| Document |
Document Title |
|
WO/2021/218953A1 |
Disclosed in the present invention is an anti-human C5 protein antibody or an antigen-binding fragment thereof. The antibody or antigen-binding fragment thereof binds to human C5 protein with high affinity, blocks cleavage of C5 protein ...
|
|
WO/2021/215836A1 |
The present invention relates to a pharmaceutical composition or health functional food for treating or preventing eye diseases, comprising a verbenone derivative and a pharmaceutically acceptable salt thereof as active ingredients. More...
|
|
WO/2021/213891A1 |
The invention relates to the use of an isoquinoline multifunctional ligand, amino-7 triethoxy-4, 5,6 oxo-1 dihydro-1, 3 isobenzofurannyl-3) - 1methoxy-8 methyl-2 methylenedioxy 6,7tetrahydro -, 2,3, 4isoquinoline, or tritoqualine for the...
|
|
WO/2021/213512A1 |
A pharmaceutical composition for ophthalmic dosing or administration is disclosed, comprising (i) a compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; and (ii) at leas...
|
|
WO/2021/212686A1 |
A method for treating retinitis pigmentosa. The method comprises the following step: enabling a subject in need to have a functional RHO gene, wherein the functional RHO gene does not contain a mutation site selected from the following g...
|
|
WO/2021/213393A1 |
Provided are compounds of Formula I and pharmaceutically acceptable salt, solvate and/or derivative thereof. Further, provided are methods of treating a disease, disorder or condition mediated or treatable by activation of SHIP1 comprisi...
|
|
WO/2021/216909A1 |
Provided herein are compositions and methods for treating, reducing, preventing, inhibiting, mitigating, ameliorating, or slowing ocular replication or infections, such as viral conjunctivitis. Certain embodiments of the present disclosu...
|
|
WO/2021/216461A1 |
Disclosed herein are methods of treating age-related retinal diseases by administering to the subject a therapeutically effective amount of a purine nucleoside phosphorylase (PNPase) inhibitor and/or a PNPase purine nucleoside substrate....
|
|
WO/2021/214066A1 |
The present invention refers to a sgRNA molecule comprising a targeting domain for specifically targeting a SNP in the BEST1 coding region of a pathologic allele, wherein said targeting domain consists of a sequence selected from the gro...
|
|
WO/2021/213485A1 |
Use of andelion and monomer compounds thereof for preparing products for killing mites. Dandelion can reduce the survival time of mites. The dandelion monomers, especially taraxerol, diosmetin and taraxasterol acetate, can significantly ...
|
|
WO/2021/214282A1 |
Despite the eye's immune-privileged status, a secondary loss of vision in some patients treated with AAV led the inventors to question the immunogenicity of AAV vectors after a subretinal injection. The inventors thus characterized anti-...
|
|
WO/2021/216548A1 |
Aspects of the disclosure relate to methods and compositions for treatment of certain ocular diseases and disorders, for example age-related macular degeneration (AMD). In some embodiments, the methods comprise administering a subject ha...
|
|
WO/2021/214761A1 |
Disclosed herein is a drug eluting ophthalmic device including: a body having: a posterior surface; an anterior surface; wherein a size of the body, a shape of the posterior surface, and a shape of the anterior surface configures the dev...
|
|
WO/2021/215729A1 |
The present invention relates to a fusion protein prepared by fusing a cell-penetrating peptide and FKBP. The fusion protein of the present invention can increase lacrimal secretion and effectively alleviate corneal injury and, as such, ...
|
|
WO/2021/216403A1 |
Compositions of proteoglycans and core proteins thereof and related methods of treating subjects, e.g., patients, are described. The method may include applying a composition to an eye of a subject before, during, and/or after an intraoc...
|
|
WO/2021/210646A1 |
The present invention provides an aqueous composition for enhancing transferability into ocular tissue, the aqueous composition containing epinastine or a salt thereof and a quaternary ammonium compound, wherein the content ratio of the ...
|
|
WO/2021/209975A1 |
The present invention is related to an ophthalmic liquid composition, useful for example as moisturizer, comprising as the active principle, linear low molecular weight hyaluronic acid (LMWHA).
|
|
WO/2021/210070A1 |
The purpose of the present invention is to provide a pharmaceutical composition effective for adenoviral conjunctivitis. Provided is a pharmaceutical composition for adenoviral conjunctivitis, containing an anti-adenovirus polyclonal a...
|
|
WO/2021/209039A1 |
The present invention provides a quinazoline compound, a preparation method therefor and an application thereof, and specifically relates to a compound represented by formula (I), an isomer, a hydrate, a solvate, a pharmaceutically accep...
|
|
WO/2021/209974A1 |
The present invention relates to a process for the preparation of linear low molecular weight hyaluronic acid (LMWHA) or one of its salts, obtained by chemical depolymerization in strong acidic conditions and to the low molecular weight ...
|
|
WO/2021/208937A1 |
Provided is a method for repairing a frame-shift mutation in a gene in a cell. Also provided is a method for treating a disease related to a frame-shift mutation in a subject. These methods can be used to treat diseases associated with a...
|
|
WO/2021/207312A1 |
The invention provides methods, compositions, and kits using a galectin-3 inhibitor to prevent and treat retinal nerve damage in a subject suffering from glaucoma.
|
|
WO/2021/206455A1 |
The present invention relates to a fraction extract of Melissa officinalis leaves, and a novel pharmaceutical composition and a food composition that include same.
|
|
WO/2021/205144A1 |
The invention relates to a pharmaceutically acceptable acid addition salt of: (i) S- pindolol; and (ii) an organic acid, wherein the organic acid has: a pKa1 of greater than or equal to 2.5; and a chemical formula of CxHy(CO2H)z, where x...
|
|
WO/2021/203878A1 |
An edible composition for relieving asthenopia, comprising, in parts by weight, 1-10 parts of a turmeric powder, 1-12 parts of a whole coffee fruit extract, 1-20 parts of a phospholipid complex, 1-15 parts of DHA, 0.5-5 parts of phosphat...
|
|
WO/2021/204407A1 |
The present invention concerns a new gene therapy approach to increase light-sensitivity in degenerating cones in advanced stages of rod-cone dystrophy (RCD) mediated by G-protein-gated-K+ channel (GIRK), in particular GIRK2, activated b...
|
|
WO/2021/207348A1 |
Methods of treating or preventing ocular disease caused by herpes simplex virus-1 infection are provided, and comprise administering to a subject an effective amount of a herpes simplex virus-2 (HSV-2) having a deletion of an HSV-2 glyco...
|
|
WO/2021/203779A1 |
In the present invention, novel use of a proton pump inhibitor and a derivative thereof in treatment of pulmonary arterial hypertension is found for the first time. In the present invention, a monocrotaline-induced rat pulmonary arterial...
|
|
WO/2021/203861A1 |
Provided in the present invention is an antibody that can bind to IGF-1R. The present antibody is made up of light chains and heavy chains, and light chain and heavy chain variable domains thereof are one selection among the groups SEQ I...
|
|
WO/2021/200694A1 |
[Problem] To provide a novel compound that has read-through activity and is useful as an agent for preventing or treating nonsense-mutation genetic disorders. [Solution] One embodiment of the present invention provides a compound represe...
|
|
WO/2021/201036A1 |
The present invention provides a target protein degradation inducing compound which is a bifunctional compound having, at one terminal, a portion that binds to VHL which is a substrate recognition protein of a ubiquitin ligase complex an...
|
|
WO/2021/201170A1 |
The present invention addresses the problem of providing a novel screening technology for selecting useful drug compounds. The present invention, which solves the problem, is a method for screening for drug active ingredients, comprisi...
|
|
WO/2021/202398A1 |
Embodiments of an improved photodynamic therapy device are provided. An example of the device includes an irradiation head having a first end and a surface at a second end, the surface having a radius of curvature. The device also includ...
|
|
WO/2021/198844A1 |
Compound of formula (I) wherein R1 is selected from the group consisting of: H, Me, OH; R2 is selected from the group consisting of: H, OH, Me, t-Bu, Et, OMe, Pr, Allyl; R3 is selected from the group consisting of: H, OH, Me, Cl, F; R4 i...
|
|
WO/2021/195876A1 |
Provided are a nucleic acid encoding a human nuclear factor E2-related factor 2 (Nrf2) protein and a nucleotide sequence of the nucleic acid. Also provided are a recombinant expression vector containing the nucleic acid and a transforman...
|
|
WO/2021/198212A1 |
The invention relates to an ophthalmic formulation in form of an oil-in-water microemulsion comprising oil particles dispersed in a continuous water phase and its uses. The formulation comprises 0.01 - 20.0 weight-%, preferably 0.1 - 2.0...
|
|
WO/2021/202680A2 |
The present invention provides compositions comprising phosphatidylcholine derived compounds carrying an omega-3 fatty acid for use in prophylaxis or therapy, particularly when administered systemically. This invention further relates to...
|
|
WO/2021/198369A1 |
The present invention relates to a pharmaceutical composition comprising an epidermal growth factor receptor (EGFR) agonist for use in the treatment of a retinal pigment epithelium (RPE) damage associated disease in a patient, wherein th...
|
|
WO/2021/195904A1 |
Provided is the use of a composition containing Astragali radix, Puerariae lobatae radix and Erigerontis herba in the preparation of a drug for treating glaucoma and ocular hypertension in individuals.
|
|
WO/2021/202986A1 |
The disclosure provides therapeutic compounds, compositions (e.g., therapeutic agents or medicaments) and methods for preventing or treating mitochondrial disease such as Friedreich's ataxia in a mammalian subject, reducing risk factors,...
|
|
WO/2021/198116A1 |
The invention relates to formulations comprising a halogenated salicylanilide, or a pharmaceutically acceptable salt thereof, and a cyclodextrin. The formulations may be in the form of a liquid formulation, particularly an aqueous formul...
|
|
WO/2021/198254A1 |
The present invention refers to Biochanin A derivative as defined in formula (II) or a salt thereof for use in a method of treating or preventing BEST1-related retinopathies such as autosomal dominant Best vitelliform macular dystrophy. ...
|
|
WO/2021/197283A1 |
The invention discloses a synthetic peptide amide compound, which belongs to the field of medicine, and specifically discloses a synthetic peptide amide compound containing a boronic acid group and a preparation method thereof. The inven...
|
|
WO/2021/199814A1 |
The present invention pertains to an ophthalmic aqueous composition containing a silver salt, wherein a polyester resin container or a polyolefin (excluding polypropylene) resin container is filled with the ophthalmic aqueous composition...
|
|
WO/2021/199813A1 |
The present invention makes it possible to prepare a rebamipide-containing aqueous suspension that has similar properties to Mucosta® ophthalmic suspension UD2%, without using PVA as an additive, from an aqueous suspension that contains...
|
|
WO/2021/195176A1 |
This invention relates to methods and compositions for treating diseases of intraocular pressure. More particularly, this invention discloses a range of compounds, devices and methods for detecting and/or affecting intraocular pressure, ...
|
|
WO/2021/193732A1 |
The present invention addresses the issue of providing a modified photoreceptive chloride channel that has a narrow wavelength sensitivity range, has both short τon and short τoff, and has excellent photoreactivity. The solution is a p...
|
|
WO/2021/191359A1 |
Fused and bridged compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them in...
|
|
WO/2021/191525A1 |
The present invention relates to a platelet lysate foam obtained from a blood derivative (allogenic or autologous) which conserves the biological properties of the platelet lysates and has optimum properties, in particular mechanical pro...
|
|
WO/2021/191461A1 |
The present invention relates to an insulin sensitizer for use in the prevention and/or treatment of the damages caused by retinal detachment, and in particular for preventing or treating the loss of vision induced by retinal detachment.
|
